CL2009001156A1 - Acetato de un peptido de 12 aminoacidos; metodo de preparacion; composicion farmaceutica y agente que lo contiene, solo o conjuntamente con un principio activo que dana el acido nucleico; util para el tratamiento o profilaxis de trastornos proliferativos celulares. - Google Patents
Acetato de un peptido de 12 aminoacidos; metodo de preparacion; composicion farmaceutica y agente que lo contiene, solo o conjuntamente con un principio activo que dana el acido nucleico; util para el tratamiento o profilaxis de trastornos proliferativos celulares.Info
- Publication number
- CL2009001156A1 CL2009001156A1 CL2009001156A CL2009001156A CL2009001156A1 CL 2009001156 A1 CL2009001156 A1 CL 2009001156A1 CL 2009001156 A CL2009001156 A CL 2009001156A CL 2009001156 A CL2009001156 A CL 2009001156A CL 2009001156 A1 CL2009001156 A1 CL 2009001156A1
- Authority
- CL
- Chile
- Prior art keywords
- prophylaxis
- acetate
- alone
- useful
- conjunction
- Prior art date
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Acetato de un péptido de 12 aminoácidos; método de preparación; composición farmacéutica y agente que lo contiene, solo o conjuntamente con un principio activo que daña el ácido nucleico; útil para el tratamiento o profilaxis de trastornos proliferativos celulares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5319008P | 2008-05-14 | 2008-05-14 | |
| US11684908P | 2008-11-21 | 2008-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2009001156A1 true CL2009001156A1 (es) | 2010-08-27 |
Family
ID=40886711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2009001156A CL2009001156A1 (es) | 2008-05-14 | 2009-05-13 | Acetato de un peptido de 12 aminoacidos; metodo de preparacion; composicion farmaceutica y agente que lo contiene, solo o conjuntamente con un principio activo que dana el acido nucleico; util para el tratamiento o profilaxis de trastornos proliferativos celulares. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20100112089A1 (es) |
| CN (1) | CN102149725A (es) |
| AR (1) | AR071774A1 (es) |
| CL (1) | CL2009001156A1 (es) |
| PE (1) | PE20091924A1 (es) |
| RU (1) | RU2010150964A (es) |
| TW (1) | TW201000116A (es) |
| UY (1) | UY31826A (es) |
| WO (1) | WO2009139497A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110133296B (zh) * | 2012-03-18 | 2022-03-25 | 镜株式会社 | 疾病样品分析装置、分析系统及分析方法 |
| EP3013351B1 (en) | 2013-06-24 | 2019-10-30 | CanBas Co., Ltd. | Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations |
| GB201401877D0 (en) | 2014-02-04 | 2014-03-19 | Univ Tromsoe | Peptides |
| US10149887B2 (en) * | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| TWI805542B (zh) * | 2015-10-23 | 2023-06-21 | 日商坎巴斯有限公司 | 用於癌症治療之肽及擬肽與t細胞活化劑及/或查核點抑制劑之組合 |
| WO2017087235A1 (en) | 2015-11-20 | 2017-05-26 | Senhwa Biosciences, Inc. | Combination therapy of tetracyclic quinolone analogs for treating cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4610828B2 (ja) * | 1999-09-22 | 2011-01-12 | 株式会社 キャンバス | G2期細胞周期停止の阻害、およびdna損傷剤に対する細胞感作のための組成物および方法 |
| CN100360564C (zh) * | 2002-01-17 | 2008-01-09 | 坎巴斯有限公司 | 具有抗增殖活性和/或可增强核酸损伤剂或治疗的效果的肽和肽模拟物 |
| US7125842B2 (en) * | 2003-04-07 | 2006-10-24 | Canbas Co. Ltd. | Anti-fungal compounds and methods of use |
| JP2007501608A (ja) * | 2003-08-08 | 2007-02-01 | 株式会社 キャンバス | 抗癌治療の効力を推定するための感受性試験 |
| AU2006201635A1 (en) * | 2005-10-20 | 2007-05-10 | Ludwig Institute For Cancer Research | Novel inhibitors and methods for their preparation |
| CA2666184A1 (en) * | 2006-10-11 | 2008-04-17 | Medvet Science Pty. Ltd. | The use of a dna damaging agent and a ligand for the treatment of cancer |
-
2009
- 2009-05-13 US US12/465,536 patent/US20100112089A1/en not_active Abandoned
- 2009-05-13 UY UY0001031826A patent/UY31826A/es not_active Application Discontinuation
- 2009-05-13 RU RU2010150964/04A patent/RU2010150964A/ru not_active Application Discontinuation
- 2009-05-13 AR ARP090101720A patent/AR071774A1/es not_active Application Discontinuation
- 2009-05-13 WO PCT/JP2009/059238 patent/WO2009139497A1/en not_active Ceased
- 2009-05-13 CL CL2009001156A patent/CL2009001156A1/es unknown
- 2009-05-13 PE PE2009000669A patent/PE20091924A1/es not_active Application Discontinuation
- 2009-05-13 TW TW098115779A patent/TW201000116A/zh unknown
- 2009-05-13 CN CN2009801279086A patent/CN102149725A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UY31826A (es) | 2010-01-05 |
| RU2010150964A (ru) | 2012-06-20 |
| US20100112089A1 (en) | 2010-05-06 |
| CN102149725A (zh) | 2011-08-10 |
| AR071774A1 (es) | 2010-07-14 |
| PE20091924A1 (es) | 2010-01-04 |
| TW201000116A (en) | 2010-01-01 |
| WO2009139497A1 (en) | 2009-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2541217T3 (es) | Diferenciación de células madre mesenquimales | |
| CL2012001659A1 (es) | Composición acuosa antitranspirante/desodorante que comprende a) un activo antitranspirante b) mezcla que comprende al menos una amida básica y/o una amina básica y un material de contraparte para dicha amida y/o amina y c) al menos el 10% en agua; método para producirla; y método para aplicarla. | |
| MX2014007233A (es) | Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados. | |
| BR112013018352A2 (pt) | composição de minociclina tópica e método | |
| CL2009001156A1 (es) | Acetato de un peptido de 12 aminoacidos; metodo de preparacion; composicion farmaceutica y agente que lo contiene, solo o conjuntamente con un principio activo que dana el acido nucleico; util para el tratamiento o profilaxis de trastornos proliferativos celulares. | |
| PE20110302A1 (es) | Formulacion farmaceutica de un anticuerpo contra p-selectina | |
| BR112014004460A2 (pt) | material polimérico para um recipiente isolado | |
| AR082805A1 (es) | PEPTIDO O COMPLEJO PEPTIDICO QUE SE UNE A INTEGRINA a2 Y METODOS Y USOS QUE IMPLICAN A LOS MISMOS | |
| PE20130579A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa | |
| EA201391331A1 (ru) | Активные и селективные ингибиторы nav1.3 и nav1.7 | |
| MX2014004725A (es) | Formulaciones de etanercept estabilizadas con aminoacidos. | |
| IN2014KN01713A (es) | ||
| IN2014KN01714A (es) | ||
| IN2014KN01716A (es) | ||
| WO2012145665A3 (en) | Method of drug delivery for pth, pthrp and related peptides | |
| WO2012103038A9 (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
| UY31209A1 (es) | Uso de homo y copolimeros para la estabilización de formulaciones de principios activos | |
| MX2014001372A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| EP4403579A3 (en) | Formulation for anti-alpha4beta7 antibody | |
| WO2008128775A3 (en) | Stabilised pharmaceutical composition containing pregabaline | |
| WO2011146922A3 (en) | Materials and methods for treatment of inflammation | |
| MX2012003565A (es) | Agentes de despeje de peptido. | |
| BR112012027080A2 (pt) | composições orgânicas para tratar doenças relacionadas a beta - ena | |
| BR112013004455A2 (pt) | composições para fornecimento gástrico de agentes ativos | |
| CL2009000803A1 (es) | Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada |